UpDoc gets FDA clearance for clinical AI
UpDoc received FDA clearance for clinical AI software designed to support care between doctor visits.
Clinical AI is moving from back-office support toward regulated patient-care workflows. UpDoc’s clearance is a sign that patient-facing AI tools are starting to enter higher-stakes healthcare settings.
What happened
UpDoc received FDA clearance for clinical AI software designed to support care between doctor visits under clinician oversight.
The company is initially focused on chronic-care workflows and has secured $18M in seed funding from investors including S32, Polaris Partners, Mayo Clinic and the American Diabetes Association’s innovation fund.
Why it matters
This is a strong healthtech signal.
Most healthcare AI has focused on documentation, scheduling and back-office automation. UpDoc points to a more regulated category where AI helps extend care between visits while keeping clinicians in control.
The bigger picture
Healthcare systems are under pressure from workforce shortages and rising care needs. Regulated AI tools that safely support patients between appointments could become important infrastructure for scaling clinical capacity.